Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists.

Since glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been licensed for the treatment of type 2 diabetes mellitus and obesity, they were one of the first drug classes to be examined in individuals with MASLD/MASH.

由于胰高血糖素样肽-1受体激动剂（GLP-1RAs）已被批准用于2型糖尿病和肥胖症的治疗，它们是最早被检查用于MASLD/MASH患者的药物类别之一。

Successful phase 2 randomised clinical trials with these agents have resulted in progression to phase 3 clinical trials (principally testing the long-term efficacy of subcutaneous semaglutide).

这些药物在第二阶段随机临床试验中取得了成功，导致了进入第三阶段临床试验（主要测试皮下注射司美格鲁肽的长期疗效）。

Over the last few years, in addition to GLP-1RAs, newer agents with glucose-dependent insulinotropic peptide and/or glucagon receptor agonist functions have been tested, with increasing evidence from phase 2 randomised clinical trials of histological improvements in MASLD/MASH, as well as benefits on MASLD-related extrahepatic complications.

在过去的几年里，除了GLP-1RAs，一些具有葡萄糖依赖性胰岛素促进肽和/或胰高血糖素受体激动剂功能的新药物也得到了测试，第二阶段随机临床试验的证据越来越多地表明，这些药物在MASLD/MASH的组织学改善以及MASLD相关肝外并发症的益处方面有显著效果。

Based on this background of evidence, single, dual or triple incretin receptor agonists are becoming an attractive and promising treatment option for MASLD or MASH, particularly in individuals with coexisting obesity or type 2 diabetes mellitus.

基于这些证据背景，单一、双重或三重肠促胰岛素受体激动剂正在成为MASLD或MASH的有吸引力且有前景的治疗选择，特别是在同时存在肥胖或2型糖尿病的个体中。

In this narrative review, we examine the rapidly expanding body of clinical evidence supporting a role of incretin-based pharmacotherapies in delaying or reversing MASH progression.

在这篇叙述性综述中，我们检查了迅速增长的临床证据，这些证据支持肠促胰岛素基础药物治疗在延缓或逆转MASH进展中的作用。

We also discuss the biology of incretins and the putative hepatoprotective mechanisms of incretin-based pharmacotherapies for managing MASLD or MASH.

我们还将讨论肠促胰岛素的生物学以及基于肠促胰岛素的药物治疗在管理MASLD或MASH中的假定肝脏保护机制。